Efavirenz | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Grow Your Pharma Business Digitally

X

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Efavirenz
US Patents

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Efavirenz

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 28 USDMF, 13 EU WC, 2 KDMF, 22 NDC API, 20 Listed Suppliers, $ API Reference Price

41 API Suppliers
28 USDMF
13 EU WC
2 KDMF
22 NDC API
20 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

197 FDF Dossiers, 59 FDA Orange Book, 40 Europe, 11 Canada, 67 South Africa, 20 Listed Dossiers

197 FDF Dossiers
59 FDA Orange Book
40 Europe
11 Canada
67 South Africa
20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 400MG;300MG;300MG, CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 600MG, TABLET;ORAL - 600MG;200MG;300MG

TABLET;ORAL - 400MG;300MG;300MG
CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 600MG
TABLET;ORAL - 600MG;200MG;300MG

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 10 DKSH, 4 Faran Shimi Pharmaceutical, 5 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 14 BASF, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 12 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 12 Sigachi Industries, 2 The Dow Chemical Company, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

52 Coating Systems & Additives, 45 Fillers, Diluents & Binders, 28 Controlled & Modified Release, 24 Disintegrants & Superdisintegrants, 22 Thickeners and Stabilizers, 17 Granulation, 16 Lubricants & Glidants, 14 Direct Compression, 10 Topical, 9 Empty Capsules, 8 Film Formers & Plasticizers, 7 Co-Processed Excipients, 6 Taste Masking, 5 Solubilizers, 5 Rheology Modifiers, 5 API Stability Enhancers, 5 Coloring Agents, 4 Emulsifying Agents, 4 Vegetarian Capsules, 3 Chewable & Orodispersible Aids, 3 Parenteral, 1 Surfactant & Foaming Agents

52 Coating Systems & Additives
45 Fillers, Diluents & Binders
28 Controlled & Modified Release
24 Disintegrants & Superdisintegrants
22 Thickeners and Stabilizers
17 Granulation
16 Lubricants & Glidants
14 Direct Compression
10 Topical
9 Empty Capsules
8 Film Formers & Plasticizers
7 Co-Processed Excipients
6 Taste Masking
5 Solubilizers
5 Rheology Modifiers
5 API Stability Enhancers
5 Coloring Agents
4 Emulsifying Agents
4 Vegetarian Capsules
3 Chewable & Orodispersible Aids
3 Parenteral
1 Surfactant & Foaming Agents

DIGITAL CONTENT

55 News #PharmaBuzz

55 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 24 Regulatory FDF Prices, 15 Annual Reports

3 US Medicaid Prescriptions
24 Regulatory FDF Prices
15 Annual Reports

MARKET PLACE

8 APIs, 5 FDF Dossiers

8 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

5 US Patents, 10 Health Canada Patents

5 US Patents
10 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 USP, 5 Others

5 USP
5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 95 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

5 All

01 5GILEAD SCIENCES

filter Patent Number Reset all filters

5 All

01 18598185

02 29018192

03 29545414

filter API Patent Reset all filters

5 All

01 5Blank

filter FDF Patent Reset all filters

5 All

01 3Y

02 2Blank

filter Expiration Date Reset all filters

5 All

01 42026-06-13

02 12029-04-28

Product Main Page

01

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

ELCC

Not Confirmed

GILEAD SCIENCES

ELCC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9018192

Drug Substance Claim :

Drug Product Claim :

Application Number : 21937

Patent Use Code : U-750

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

ELCC

Not Confirmed

GILEAD SCIENCES

ELCC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9545414

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-1170

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

ELCC

Not Confirmed

GILEAD SCIENCES

ELCC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9545414

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-750

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

ELCC

Not Confirmed

GILEAD SCIENCES

ELCC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9018192

Drug Substance Claim :

Drug Product Claim :

Application Number : 21937

Patent Use Code : U-1170

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

ELCC

Not Confirmed

GILEAD SCIENCES

ELCC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-04-28

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 8598185

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-04-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!